- Home
- MEGL vs PMCB Comparison
MEGL vs PMCB Comparison
Compare MEGL & PMCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MEGL | PMCB |
|---|---|---|
| Founded | 2016 | 1996 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.6M | 6.6M |
| IPO Year | 2022 | N/A |
Fundamental Metrics
Financial Performance| Metric | MEGL | PMCB |
|---|---|---|
| Price | $1.28 | $0.78 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 17.7K | ★ 3.1M |
| Earning Date | 12-11-2025 | 12-15-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.01 |
| Revenue | ★ $1,296,394.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $118.70 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.02 | $0.63 |
| 52 Week High | $5.52 | $1.90 |
Technical Indicators
Market Signals| Indicator | MEGL | PMCB |
|---|---|---|
| Relative Strength Index (RSI) | 45.45 | 47.04 |
| Support Level | $1.22 | $0.71 |
| Resistance Level | $1.34 | $1.20 |
| Average True Range (ATR) | 0.07 | 0.13 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 50.00 | 27.12 |
Price Performance
Historical ComparisonAbout MEGL Magic Empire Global Limited
Magic Empire Global Ltd is a financial services provider in Hong Kong which principally engage in the provision of corporate finance advisory services and underwriting services. The companys offerings mainly comprise of IPO sponsorship services, Financial advisory and independent financial advisory services, Compliance advisory services, Underwriting services, Corporate service.
About PMCB PharmaCyte Biotech Inc.
PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.